offer
all report title image
  • Published On : Sep 2022
  • Code : CMI4152
  • Industry : Pharmaceutical
  • Pages : 170
  • Formats :

The global lice treatment market was valued at US$ 937.4 Mn in 2021 and is forecast to reach a value of US$ 1,413.3 Mn by 2028 at a CAGR of 6.0% between 2022 and 2028. The global lice treatment market is experiencing strong growth owing to the increasing prevalence of lice infestation and easy availability of lice treatment products. Moreover, rise in awareness among people is expected to boost growth of the market. However, factors such as lack of awareness and less healthcare expenditure in developing countries are expected to hamper the growth of the global lice treatment market.

Global Lice Treatment Market: Regional Insights

Based on geography, the global lice treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period owing to the increasing children population in this region. For instance, head lice are a common problem, especially for kids. Head lice can make the child's scalp itchy and irritated, and scratching can lead to an infection. According to the United States Census Bureau, in 2020, the number of children under the age of 18 years was 73.1 million. This in turn is expected to increase demand for lice treatment in the U.S.

Europe is also expected to witness robust growth in the global lice treatment market due to the increasing children population and the presence of a larger infestation pool in this region. For instance, in Europe, the infection infect between 1 and 20% of different groups of people. Head-lice infestations are common, especially in children.

Figure 1. Global Lice Treatment Market Share (%), by Region, 2021

Lice Treatment  | Coherent Market Insights

Global Lice Treatment Market Drivers:

Increasing prevalence of head lice across the globe is expected to augment growth of the global lice treatment market over the forecast period. For instance, head lice infestation was associated with densely populated areas, more children or people in one household, longer hair, female sex, and/or brown hair color. According to European Centre for Disease Prevention and Control (ECDC), head lice infest more than 100 million people worldwide. Moreover, according to U.S. CDC, an estimated 6 million to 12 million infestations occur each year in the United States among children 3 to 11 years of age.

Increasing demand for lice treatment around the world is expected to boost the growth of the global lice treatment market over the forecast period. For instance, in August 2020, Hatchtech announced that its commercialisation partner, Dr Reddy’s Laboratories, has achieved US Food and Drug Administration (FDA) approval of Xeglyze (abametapir) Lotion 0.74% for the topical treatment of head lice infestation in patients 6 months of age and older.

Global Lice Treatment Market Opportunities:

Increasing focus on the development of lice treatment is expected to provide significant growth opportunities for players in the global lice treatment market. For instance, with the increasing prevalence of lice, the demand for safe and effective treatment is also increasing with a rapid pace. In February 2021, Benchmark planned to launch its novel lice treatment. Large-scale trials of Benchmark’s BMK08 medicine and the CleanTreat filtering system have proved the combination to be extremely effective against lice without impacting the environment.

Increasing awareness among people worldwide about lice and related treatments is expected to offer lucrative growth opportunities for players in the lice treatment market. For instance, as a health problem, millions of individuals are infested with lice every year worldwide. September is national head lice prevention month! It is an annual reminder to parents about the importance of routine screening and sending their children to school free of lice and nits.

CMI table icon

Lice Treatment Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2021: US$ 937.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2022 to 2028 CAGR: 6.0% 2028 Value Projection: US$ 1,413.3 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: OTC Medication (Permethrin, Pyrethrin, Other Product Types), Prescription Medication (Ivermectin, Spinosad, Malathion, Other Prescription Medications)
  • By Distribution Channel: Hospitals and Clinics, Retail Pharmacies, and Other Distribution Channels
Companies covered:

Fleming Medical Ltd., Parapro Pharmaceuticals, Prestige Consumer Healthcare Inc., Perrigo company plc (Omega Pharma), Alliance Pharmaceuticals Ltd., Oystershell Consumer Health (Bayer), Johnson and Johnson Services, Inc., GlaxoSmithKline, and Arbor Pharmaceuticals Inc. (Azurity Pharmaceuticals), among others.

Growth Drivers:
  • Increasing prevalence of lice infestation
  • Increasing demand for safe and effective lice treatment
Restraints & Challenges:
  • Lack of awareness among people
  • Less healthcare expenditure in developing countries

Global Lice Treatment Market Trends:

Frequent approvals and launches of novel products by market players is expected to propel the growth of the global lice treatment market. For instance, in October 2020, the U.S. Food and Drug Administration (FDA) approved a lotion to treat head lice for nonprescription, or over-the-counter (OTC), use through a process called a prescription (Rx)-to-OTC switch.

Easy availability of lice treatment products is expected to augment the growth of the global lice treatment market. For instance, Lice treatment products are available over-the-counter or with a prescription. Lice treatment products, such as lotions, shampoos, and cream rinses, eliminate head lice. However, consult a doctor to recommend a product that’s safe to use.

Global Lice Treatment Market Restraints:

Lack of awareness among people is expected to hamper the growth of the global lice treatment market. For instance, a lack of awareness in families, regarding head lice treatment, often leads to the use of traditional remedies including the direct use of insecticides or kerosene, which can be very harmful and may ultimately lead to the death of the individual being treated.

Less healthcare expenditure in developing countries is expected to hinder growth of the global lice treatment market. For instance, the article, titled Countries Are Spending More on Health, but People Are Still Paying Too Much Out of Their Own Pockets, published in February 2019 by the WHO, governments provide 51% of country’s health spending, while more than 35% of health spending per country comes from out-of-pocket expenses.

Figure 2. Global Lice Treatment Market Share (%), by Product Type, 2021

Lice Treatment  | Coherent Market Insights

Global Lice Treatment Market Segmentation:

The global lice treatment market report is segmented into Product Type, Distribution Channel, and Region.

Based on Product Type, the market is segmented into OTC Medication and Prescription Medication. Out of which, both OTC Medication and Prescription Medication Segments are expected to dominate the lice treatment market over the forecast period and this is attributed to the increasing demand for safe and effective treatment worldwide. Lice treatment products are available over-the-counter or with a prescription. These products, help eliminate head lice.

Based on Distribution Channel, the market is segmented into Hospitals and Clinics, Retail Pharmacies, and Other Distribution Channels. Out of which, All Segments are expected to dominate the lice treatment market over the forecast period and this is attributed to the increase in prevalence of head lice across the globe.

Global Lice Treatment Market: Key Developments

In August 2021, ParaPRO announced that United States Food and drug Administration (FDA) approved Natroba (spinosad) Topical Suspension, 0.9%, the first product for scabies, available in the United States.

In October 2020, the United States Food and Drug Administration (FDA) granted the approval of nonprescription Sklice (ivermectin) lotion, 0.5% for the treatment of head lice infestations in patients 6 months of age and older to Arbor Pharmaceuticals LLC through the process called a prescription (Rx)-to-OTC switch.

In October 2019, Kaken Pharmaceuticals and Arbor Pharmaceuticals entered into a licensing agreement to develop and commercialize an anthelminthic agent ivermectin lotion, 0.5% Sklice Lotion, for the treatment of head lice, a parasitic infectious disease, in Japan.

Global Lice Treatment Market: Key Companies Insights

The global lice treatment market is highly competitive. This is attributed to the rise demand for long-term lice management, as a result, players in the market are focusing on launching safe and effective treatment in the market.

Some of the key players in the global lice treatment market are:

Fleming Medical Ltd., Parapro Pharmaceuticals, Prestige Consumer Healthcare Inc., Perrigo company plc (Omega Pharma), Alliance Pharmaceuticals Ltd., Oystershell Consumer Health (Bayer), Johnson and Johnson Services, Inc., GlaxoSmithKline, and Arbor Pharmaceuticals Inc. (Azurity Pharmaceuticals), among others.

Lice are parasitic insects that can be found on people's heads and bodies, including the pubic area. There are three types of lice that affect humans: body lice, head lice, and pubic lice. Lice are tiny, wingless insects that feed on human blood. Lice spread from person to person through close contact and by sharing belongings. Unless treated properly, this condition can become a recurring problem. Lice treatment products are available over-the-counter (OTC) and/or with a prescription. These products help eliminate lice.

Market Dynamics:

Increasing prevalence of lice infestation, easy availability of lice treatment products, and rise in awareness among people are some major factors expected to aid in the growth of the global lice treatment market during the forecast period.

In October 2020, the U.S. Food and Drug Administration (FDA) approved a lotion to treat head lice for nonprescription, or over-the-counter (OTC), use through a process called a prescription (Rx)-to-OTC switch. FDA initially approved Sklice (ivermectin) lotion, 0.5% for the treatment of head lice in patients 6 months of age and older as a prescription drug in February 2012.

In August 2020, Uniseed investee company Hatchtech, developing an innovative prescription head lice product, announced that its commercialization partner, Dr Reddy’s Laboratories, has achieved US FDA approval of Xeglyze (abametapir) Lotion 0.74% for the topical treatment of head lice infestation in patients 6 months of age and older.

Key features of the study:

  • This report provides in-depth analysis of the global lice treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global lice treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Fleming Medical Ltd., Parapro Pharmaceuticals, Prestige Consumer Healthcare Inc., Perrigo company plc (Omega Pharma), Alliance Pharmaceuticals Ltd., Oystershell Consumer Health (Bayer), Johnson and Johnson Services, Inc., GlaxoSmithKline, and Arbor Pharmaceuticals Inc. (Azurity Pharmaceuticals), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global lice treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lice treatment market.

Detailed Segmentation:

  • Global Lice Treatment Market By Product Type:
    • OTC Medication
      • Permethrin
      • Pyrethrin
      • Other Product Types
    • Prescription Medication
      • Ivermectin
      • Spinosad
      • Malathion
      • Other Prescription Medications
  • Global Lice Treatment Market By Distribution Channel:
    • Hospitals and Clinics
    • Retail Pharmacies
    • Other Distribution Channels
  • Global Lice Treatment Market By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles
    • Fleming Medical Ltd.
    • Parapro Pharmaceuticals
    • Prestige Consumer Healthcare Inc.
    • Perrigo company plc (Omega Pharma)
    • Alliance Pharmaceuticals Ltd.
    • Oystershell Consumer Health (Bayer)
    • Johnson and Johnson Services, Inc.
    • GlaxoSmithKline
    • Arbor Pharmaceuticals Inc. (Azurity Pharmaceuticals)

Frequently Asked Questions

The global lice treatment market size is estimated to be valued at US$ 993.5 Million in 2022 and is expected to exhibit a CAGR of 6.0% between 2022 and 2028.
Increasing prevalence of lice infestation and increasing demand for lice treatment is fueling the growth of the market.
The Prescription Medication segment is the leading product type segment in the market.
Lack of awareness and less healthcare expenditure in developing countries are major factors restraining growth of the market.
Major players operating in the market are Fleming Medical Ltd., Parapro Pharmaceuticals, Prestige Consumer Healthcare Inc., Perrigo company plc (Omega Pharma), Alliance Pharmaceuticals Ltd., Oystershell Consumer Health (Bayer), Johnson and Johnson Services, Inc., GlaxoSmithKline, and Arbor Pharmaceuticals Inc. (Azurity Pharmaceuticals), among others.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo